Table 2.
TKI therapies and tumor mutational status of the cohort
| Mutational status of primary tumors | Mutational status of resistant metastatic tumors | Death or not at the last follow-up | TKI therapy after CRS | |
|---|---|---|---|---|
| Case 1 | KIT exon 9 | KIT exon 9 | No | Imatinib |
| Case 2 | KIT exon 11 | KIT exon 11 | Yes | Imatinib + Sunitinib + Regorafenib |
| Case 3 | KIT exon 9 | KIT exon 9 | Yes | Sunitinib |
| Case 4 | KIT exon 11 | KIT exon 11 + 17 | Yes | Sunitinib + Regorafenib + Dasatinib |
| Case 5 | KIT exon 9 | KIT exon 9 | No | Imatinib + Sunitinib |
| Case 6 | KIT exon 11 | KIT exon 11 + 13 | No | Sunitinib |
| Case 7 | KIT exon 11 | KIT exon 11 | Yes | Imatinib + Sunitinib |
| Case 8 | KIT exon 11 | KIT exon 11 | No | Imatinib |
| Case 9 | KIT exon 11 | KIT exon 11 + 17 | No | Sunitinib |
| Case 10 | KIT exon 11 | KIT exon 11 | Yes | Imatinib + Sunitinib |
| Case 11 | KIT exon 11 | KIT exon 11 | No | Imatinib + Sunitinib + Ripretinib |
| Case 12 | KIT exon 11 + PDGFRA | KIT exon 11 + PDGFRA | No | Sunitinib |
| Case 13 | KIT exon 17 | KIT exon 17 | No | Imatinib + Dasatinib + Regorafenib |
| Case 14 | Wild type | Wild type | Yes | Imatinib + Sunitinib + Dasatinib |
| Case 15 | Wild type | Wild type | Yes | Imatinib + Sunitinib + Dasatinib |